Netscientific Share Discussion Threads

[bad robot] 28/5/2015 13:36

Beautifull

26% rise and I want another 20% for today

[bad robot] 28/5/2015 13:33

150p-154p

160p is coming


BOOOM BOOOOM

[bad robot] 28/5/2015 13:32

It's party time Chez BR again

[bad robot] 28/5/2015 13:29

The buy buy buy switch has been put in overdrive

[bad robot] 28/5/2015 13:28

BOOOM BOOOOM

[bad robot] 28/5/2015 13:28

150p about to go

[bad robot] 28/5/2015 13:28

Here's my 150p, and 150p buys in.

[bad robot] 28/5/2015 13:25

This should be up 30% today

[bad robot] 28/5/2015 13:25

tick up again

[bad robot] 28/5/2015 13:23

right on time.

here comes my 150p, should spike to 160p

[bad robot] 28/5/2015 13:22

tick up is coming

[bad robot] 28/5/2015 13:21

ADVFN nonce about to get come over and red marked. LOL

[bad robot] 28/5/2015 13:19

c'mon baby

I want to see 150p

[bad robot] 28/5/2015 13:17

TIDMNSCI

NetScientific PLC

28 May 2015

NetScientific plc

("NetScientific" or the "Group")

PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy

London, UK - 28 May 2015 - NetScientific (AIM: NSCI) notes that portfolio company, PDS Biotechnology Corp., has announced positive preliminary data showing that its lead cancer immunotherapy treatment, PDS0101, has generated strong T-cell responses in pre-cervical cancer.

Currently, pre-cervical cancer is treated by surgical removal of lesions however; PDS0101 could offer an effective non-surgical alternative. Results show that it primes and activates the body's defense mechanisms (T-cells) to recognize, target, and kill precancerous and cancerous cells that display HPV viral proteins, which are responsible for over 99% of cervical cancers. The patient population tested were those most likely to develop invasive cancer as they had little to no pre-treatment immune responses to HPV-16.

The results are the first demonstration of PDS Biotechnology's proprietary synthetic immunotherapy technology, Versamune's(R) , application in human cancer. They also mirror preclinical data which showed strong T-cell responses and aggressive tumor regression with low doses of the product. The results mark an important step towards the development of next generation therapies to treat early and late stage cancers and suggest that Versamune(R) could be used by other immuno-oncology platform technologies.

Mike Boyce-Jacino, Executive Director of NetScientific and Director of PDS Biotechnology, said: "We are dedicated to building a unique transformative portfolio and investing in breakthrough therapeutic companies like PDS Biotechnology, which is at the forefront of developing immunotherapeutics.

"PDS Biotechnology's promising results represent an important milestone for the company. The combination of Versamune's(R) powerful and safe profile helps validate its potential to transform treatments for a wide range of cancers and infectious diseases. We now look forward to seeing the Phase II trials begin."

-ENDS-

[bad robot] 28/5/2015 13:16

Launching boys

150p coming

[bad robot] 28/5/2015 13:12

He's been in for a while

[bad robot] 28/5/2015 13:12

going to move again soon

[mirabeau] 28/5/2015 13:12

I think Woodford's in here

[bad robot] 28/5/2015 13:06

I think it just appeared on radar

[bad robot] 28/5/2015 13:06

rolling guys.

150p then whoooosh 200p

[bad robot] 28/5/2015 12:51

I like these pharmas companies, especially cancer orientated ones